Invention Grant
- Patent Title: Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine
-
Application No.: US17241972Application Date: 2021-04-27
-
Publication No.: US11773079B2Publication Date: 2023-10-03
- Inventor: Ticong Huang , Huifeng Xiao , Rui Zhao , Fei Liu , Wei Wei , Hongjiang Xu , Xiaojin Wang , Jingli Wu
- Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. , CENTAURUS BIOPHARMA CO., LTD.
- Applicant Address: CN Lianyungang
- Assignee: Chia Tai Tianqing Pharmaceutical Group Co, Ltd.,Lianyungang Runzhong Pharmaceutical Co., Ltd.,Centaurus Biopharma Co., Ltd.
- Current Assignee: Chia Tai Tianqing Pharmaceutical Group Co, Ltd.,Lianyungang Runzhong Pharmaceutical Co., Ltd.,Centaurus Biopharma Co., Ltd.
- Current Assignee Address: CN Jiangsu; CN Jiangsu; CN Beijing
- Agency: Kilpatrick Townsend & Stockton LLP
- Priority: CN 1710047243.4 2017.01.22 CN 1710570764.8 2017.07.13
- The original application number of the division: US16479459
- Main IPC: A61K31/53
- IPC: A61K31/53 ; C07D251/18 ; C07D401/14

Abstract:
The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
Public/Granted literature
- US20210246119A1 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF Public/Granted day:2021-08-12
Information query